soma1 enzymes (Conney, 1967) , and it has recently 1. Phenobarbitone in a dose of 180 mg daily was administered to ten normal subjects for 3 weeks. There was a significant increase in total plasma cholesterol, plasma low-density-lipoprotein cholesterol, plasma low-density-lipoprotein (LDL) triglycerides and plasma LDL protein. The increase in plasma LDL cholesterol accounted for the increase in total plasma cholesterol. There was a significant been suggested that the induction of microsomal enzymes may be an important factor determining plasma Iipid concentrations (Martin, Martin 8c Goldberg, 1975) . The present study has examined the influence of phenobarbitone on plasma lipid concentrations and on the relation between these and antipyrine clearance, the latter being used as an index of hepatic microsomal enzyme activity. reduction in the ratio of LDL cholesterol ;o LDL protein.
1.
Phenobarbitone in a dose of 180 mg daily was administered to ten normal subjects for 3 weeks. There was a significant increase in total plasma cholesterol, plasma low-density-lipoprotein cholesterol, plasma low-density-lipoprotein (LDL) triglycerides and plasma LDL protein. The increase in plasma LDL cholesterol accounted for the increase in total plasma cholesterol. There was a significant been suggested that the induction of microsomal enzymes may be an important factor determining plasma Iipid concentrations (Martin, Martin 8c Goldberg, 1975) . The present study has examined the influence of phenobarbitone on plasma lipid concentrations and on the relation between these and antipyrine clearance, the latter being used as an index of hepatic microsomal enzyme activity. reduction in the ratio of LDL cholesterol ;o LDL protein.
2. No significant changes were observed in total Subjects and methods plasma triglycerides, plasma very-low-density-lipoprotein (VLDL) triglycerides, plasma VLDL cholesterol or plasma VLDL protein.
3. Evidence that drug-metabolizing enzymes were induced by phenobarbitone was provided by an increase in antipyrine clearance. No relationship was observed between changes in plasma cholesterol and changes in antipyrine clearance. Serum y-glutamyl transpeptidase was also increased after phenobarbitone administration, the increase being unrelated to changes in antipyrine clearance or plasma cholesterol.
Subjects and design of study
Seven healthy male and three healthy female volunteer subjects, aged 20-30 years, gave their informed consent to participate in the study, which had bee-n approved by an ethical committee. All subjects maintained their normal diet throughout the investigation and avoided any excessive alcohol intake. None of the women was taking an oral contraceptive. All medication was excluded for at least 2 weeks before and during the study.
Each subject received phenobarbitone 180 mg daily (30 mg twice during the day and 120 mg at bed&e) o&y for 3 weeks. The following were determined initially and at the end of the period on phenobarbitone: total plasma cholesterol and triglycerides, plasma very-low-density-lipoprotein (VLDL) cholesterol, plasma VLDL") triglycerides,
Introduction
Phenobarbitone is known to induce hepatic microMedicine, Bristol Royal Infirmary, Bristol BS2 8HW, U.K.
P . N . Durrington et al.
y-glutamyl transpeptidase activity. All blood samples for lipid analysis were collected without stasis after a fast for 11 h into bottles containing dipotassium EDTA and plasma was separated by centrifugation within 1 h of collection. Phenobarbitone concentrations were measured before the first dose of the day at the end of the second week.
Data from before and after phenobarbitone administration were compared by Student's paired t-test.
Methods
Ultracentrifugation ofplasma. VLDL was obtained as the supernatant after ultracentrifugation of 5 ml of plasma on the day of collection for 24 hat 100 OOOg
The density of the infranatant was adjusted to 1.063 g/ml by addition of a solution of sodium chloride and potassium bromide (Havel, Howard & Bragdon, 1955) Serum phenobarbitone concentrations were measured by gas-liquid chromatography (Toseland, Grove & Berry, 1972) .
Antipyrine clearance. Antipyrine (1200 mg) was dissolved in 50 ml of water and administered orally to fasting subjects. Blood samples were taken at 10 min intervals for the first hour and then at 3, 5, 7, 9, 15 and 24 h. Antipyrine was assayed by a spectrophotometric method (Brodie, Axelrod, Soberman & Levy, 1949) . The half-life ( h S ) and theoretical plasma concentration at time zero (CP,) were determined by least-square regression analysis of log plasma concentration against time. Antipyrine clearance was calculated (Rowland, Benet & Graham, 1973) as Dose 0.693
Results

Totalplasma lipids, plasma VLDL andLDL lipids, and plasma VLDL and LDL protein
Initial concentrations of total plasma cholesterol and triglycerides (Tables 1 and 2) were in the normal range for our laboratory. Plasma VLDL triglycerides and plasma LDL cholesterol and triglycerides (Tables 1 and 2) were in the normal range found by Lewis, Chait, Wootton, Oakley, Krikler, Sigurdsson, February & Birkhead (1974) for a healthy London population. Nine subjects showed an increase in both total plasma cholesterol and plasma LDL cholesterol after phenobarbitone administration (Table 1) and this was statistically significant for the whole group. Increases in total plasma cholesterol both in individual subjects and the whole group were closely Table 2) . Eight subjects showed a rise in total plasma triglycerides ( Table 2 ) and six an increase in plasma VLDL triglycerides (Table 2) but the changes were not significant for the group. There was, however, a significant increase in plasma LDL triglycerides (Table 1) .
There was a significant increase in plasma LDL protein concentration (Table 1) but not in plasma VLDL protein concentration ( Table 2 ). The ratio of plasma LDL cholesterol to protein was significantly reduced after phenobarbitone administration whereas the ratios of VLDL cholesterol to protein, of VLDL triglyceride to protein and of LDL triglyceride to protein were unaltered.
Antipyrine clearance
Absorption of antipyrine was rapid and peak plasma concentrations were obtained in all subjects within 1 h of ingestion. Phenobarbitone induced an increase in the antipyrine clearance of all subjects.
The mean initial antipyrine clearance was 43 + 5 ml/ min ( ASEM) and after phenobarbitone was 78 + 8 ml/min, a mean increase of 90 f 14%. There was no correlation between the alterations in plasma lipids and in antipyrine clearance irrespective of whether these were expressed as absolute or percentage change.
Serum y-glutamyl transpeptidase
Initial serum activities of the enzyme were all within the normal range for our laboratory, the mean value for the group being 12k2.0 i.u./l (~s E M ) .
There was a signscant increase after phenobarbitone administration to a mean value of 26 + 8.0 i.u./l, a mean increase of 95 L-33%. In two subjects the activities were elevated out of the normal range. There was no correlation between the changes in serum y-glutamyl transpeptidase and any of those which occurred in plasma lipids. Changes in serum y-glutamyl transpeptidase were also unrelated to changes in antipyrine clearance.
Serum phenobarbitone
Concentrations were in the range 16-27 pg/ml (mean 20-5 pglml), confirming that all subjects were taking the phenobarbitone. There was no correlation between serum phenobarbitone concentrations and changes in lipids or changes in antipyrine clearance.
Discussion
The present study has shown a significant increase in total plasma cholesterol due to an increase in plasma LDL cholesterol in normal young subjects taking phenobarbitone for 3 weeks. Similar rises in total serum cholesterol during phenobarbitone administration for periods of up to 18 days have previously been reported in three out of four normal subjects (Miller & Nestel, 1973) . As regards a possiblt mechanism for these findings, increased hepatic cholesterol synthesis has been demonstrated in phenobarbitone-treated hamsters (Jones & Armstrong, 1965 ) and rats (Middleton & Isselbacher, 1969; Wada, Hirata & Sakamoto, 1967) . This probably results from induction of the microsomal enzyme 3-hydroxy-3-methylglutaryl-CoA-reductase, which is a rate-limiting step in cholesterol bio-synthesis (Siperstein, 1970) . Phenobarbitone is a non-specific inducer of microsomal enzymes and a relationship might be expected between increases in antipyrine clearance and in cholesterol synthesis if both are due to induction of microsomal enzymes. There was, however, no significant relationship between changes in plasma cholesterol and antipyrine clearance in the present study. The plasma cholesterol concentration is not, though, solely related to the rate of cholesterol synthesis, but also to such factors as accumulation within tissue pools, degradation and elimination, which may also be altered by phenobarbitone. Thus, for example, it has been demonstrated in monkeys receiving this drug that bile salt secretion is increased (Redinger & Small, 1973) , and in rats that 7-a-hydroxylation of cholesterol, an important step in bile salt synthesis, is increased after phenobarbitone administration (Wada, Hirata, Nakao & Sakamoto, 1968; Shefer, Hauser & Mosbach, 1972 A correlation between the concentration of serum triglycerides and activity of serum y-glutamyl transpeptidase within the general population has been reported (Martin et ul., 1975) , the highest values of both occurring in patients with type IIb and type IV hyperlipoproteinaemia in whom the raised triglycerides are in the VLDL fraction of plasma. It was suggested that the raised serum y-glutamyl transpeptidase reflected increased hepatic microsomal enzyme activity in these subjects and that induction of a microsomal enzyme on the biosynthetic pathway for triglycerides was responsible for the elevated plasma triglycerides. However, other investigators have not accepted serum y-glutamyl transpeptidase as a quantitative index of microsomal enzyme induction (Rosalki, Tarlow & Rau, 1971 ; Ideo, de Franchis, del Ninno & Dioguardi, 1971; Rosalki & Rau, 1972) , and in the present study changes in serum activity of the enzyme were not related to the changes in antipyrine clearance. We found no significant rise in the total plasma triglycerides or plasma VLDL triglycerides after phenobarbitone administration for 3 weeks, by which time microsomal drug-metabolizing enzymes had been induced. Thus our results do not support the view that there is a simple relationship between plasma VLDL triglycerides and microsomal enzyme induction.
The elevation in plasma lipids observed in this study would probably constitute only a slightly increased risk of coronary artery disease in normal subjects. However, the effect of phenobarbitone over longer periods in older subjects or subjects who have other risk factors for vascular disease may be of importance.
